Drugs / SNX281
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04609579 | Nov 2020 → Jan 2024 | lymphoid hemopathy | Stingthera, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNX281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04609579 ↗ |
| Action | Activate | “SNX281 is a small molecule activator of the Stimulator of Interferon Genes (STING) protein” NCT04609579 ↗ |
| Modality | Small molecule | “SNX281 is a small molecule activator of the Stimulator of Interferon Genes (STING) protein” NCT04609579 ↗ |
| Route | Intravenous | “SNX281 will be administered as an intravenous infusion on Days 1, 8, and 15 in Cycle 1 and on Day 1 of each subsequent cycle thereafter” NCT04609579 ↗ |